Concord Biotech · NSE: CONCORDBIO · BSE: 543960

Q2 FY26 results · Jul–Sep 2025

Concord Biotech reported revenue from operations of ₹247.06 crore (down 20.4% from Q2 FY25) and net profit of ₹63.06 crore (down 34.1% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY26	Q2 FY25	YoY	Q1 FY26	QoQ
Revenue from operations	247.06	310.18	−20.4%	203.99	+21.1%
Other income	13.35	10.03	+33.2%	13.68	−2.4%
Total income	260.41	320.21	−18.7%	217.67	+19.6%
Profit before share of associates & JVs and tax	83.39	133.29	−37.4%	57.24	+45.7%
Share of profit/(loss) of associates & JVs	2.29	(2.96)		1.49
Net profit for the period	63.06	95.74	−34.1%	44.06	+43.1%
Attributable to shareholders of the company	63.58	—	—	44.06	+44.3%
EPS, basic (₹)	6.03	9.15	−34.1%	4.21	+43.2%
Net margin (%)	25.5	30.9		21.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY26	Q2 FY25	YoY	Q1 FY26	QoQ
Revenue from operations	247.06	310.18	−20.4%	203.99	+21.1%
Other income	13.43	10.03	+33.9%	13.68	−1.8%
Total income	260.49	320.21	−18.7%	217.67	+19.7%
Profit before tax	85.52	133.29	−35.8%	57.24	+49.4%
Net profit for the period	62.90	98.70	−36.3%	42.57	+47.8%
EPS, basic (₹)	6.01	9.43	−36.3%	4.07	+47.7%
Net margin (%)	25.5	31.8		20.9

Consolidated

Filed with BSE: 13 Nov 2025, 19:28 IST
Board meeting: 13 Nov 2025
Period: 01 Jul 2025 to 30 Sep 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Nov 2025, 19:28 IST
Board meeting: 13 Nov 2025
Period: 01 Jul 2025 to 30 Sep 2025
Review status: Unaudited
Source: XBRL filing on BSE